Serum Cyfra21-1 in 27 non-adenocarcinoma EGFR-mutated patients was significantly higher than in 218 EGFR-mutated adenocarcinoma cases (median: 3.91 versus 2.50 ng/ml, P = 0.014). Here, EGFR is linked to adenocarcinoma.